Panagiotis Baxevanos

Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort

Giulio Metro, Alfredo Addeo, Diego Signorelli et al. · Journal of Thoracic Disease · 2019 · 44 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

PD-1 and PD-L1 as immunotherapy targets and biomarkers in non-small cell lung cancer.

Nikolaos Tsoukalas, Maria Kiakou, Konstantinos Tsapakidis et al. · PubMed · 2020 · 41 citations

Life Sciences, Immunology, Oncology +17

Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab

Alex Friedlaender, Giulio Metro, Diego Signorelli et al. · Acta Oncologica · 2020 · 38 citations · Full text

Medicine, Oncology, Pharmacology +14

Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy

Giannis Mountzios, Alessandro De Toma, Panagiota Economopoulou et al. · Clinical Lung Cancer · 2020 · 29 citations

Medicine, Oncology, Pharmacology +10

Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non–Small Cell Lung Cancer With a PD-L1 Expression ≥50%

Giulio Metro, Giuseppe Luigi Banna, Diego Signorelli et al. · Journal of Immunotherapy · 2020 · 28 citations

Medicine, Oncology, Pharmacology +17